Researchers from the La Jolla Institute for Immunology (LJI) and collaborators have presented a new platform to identify and validate neoantigens that would otherwise escape traditional routine sampling methods. The project, which they describe in an article published on Feb. 28, 2024, in Science Translational Medicine, started after discussions at the beginning of a cancer vaccine program between teams at UCSD Moores Cancer Center (MCC) and LJI. Read More
T-cell-engaging antibodies (TCEs) are synthetic molecules that redirect T cells to bind to the antigens on the surface of cancer cells to promote tumor elimination. In the case of multiple myeloma (MM), the approvals of anti-CD38 monoclonal antibodies (MAbs), chimeric antigen receptor T-cell therapies (CAR T) targeting B-cell maturation antigen (BCMA) or, more recently, bispecific TCEs represent great advances, but some patients still relapse after treatment. Read More
Imunon Inc. has released promising results from a live virus challenge study conducted by the Wistar Institute with IMNN-101 against the SARS-CoV-2 variant XBB.1.5. This study was conducted using the clinical vector that Imunon intends to bring into its phase I study during the second quarter, and showed IMNN-101 immunogenicity and protective activity in a live viral mouse challenge. Read More
Psoriatic arthritis mutilans (PAM) is a rare variant and the most severe form of psoriatic arthritis where patients present erosions of the small joints and osteolysis leading to joint disruption and shortening of one or more digits. To date, no susceptibility genes have been determined. Read More
Igc Pharma Inc. has reported results of preclinical studies investigating TGR-63 as a treatment for Alzheimer’s disease, showing enhanced memory function in an Alzheimer’s mouse model, including improved memory acquisition, consolidation and retrieval. Read More
Discover a wealth of industry insights with BioWorld’s extensive collection of infographics, covering the latest trends and developments in both biopharma and med-tech. Our weekly infographics are curated to provide concise summaries of key topics: financings (IPOs, private financings, public/other and follow-on offerings), deals and M&As (top deals, and monthly value and volume), regulatory (including U.S. FDA and worldwide approvals), clinical trials and more. In addition, you’ll find access to BioWorld’s year-in-review reports, as well as special infographics about obesity, pain and addiction, biosimilars and the aging space. Read More
Tumors in the stomach and pancreas are known to express claudin 18.2 (CLDN18.2) and the absence of expression in normal tissues makes it an attractive therapeutic target. Read More
At this week’s EACR-AACR-ICAR meeting in Dublin, Suzhou Kintor Pharmaceuticals Inc. presented preclinical data for the novel MYC- and GSPT1-targeting molecular glue candidate, GT-19630, being developed for the treatment of breast cancer. Read More
Sravathi AI Technology Pvt Ltd. has disclosed ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer. Read More
Scientists at Mount Sinai School of Medicine and U.S. Department of Veterans Affairs have synthesized mothers against decapentaplegic homolog 3 (SMAD3) inhibitors reported to be useful for the treatment of renal, hepatic and pulmonary fibrosis. Read More
Macquarie University has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19). Read More
Neurenati Therapeutics has closed its seed funding round, securing CA$1.2 million (US$884,000) to advance development of therapies for various rare diseases, including pediatric conditions. Read More
University of Colorado has divulged efflux pump (bacterial) inhibitors reported to be useful for the treatment of bacterial infections, particularly, gram-negative bacterial infections. Read More
Jacobio Pharmaceuticals Group Co. Ltd. has received FDA approval of its IND application for JAB-30300, allowing it begin a phase I/IIa trial in the U.S. in advanced solid tumors. Read More
Researchers from University of Padova have presented data from a study that aimed to investigate the role of microRNAs (miRs) in the development and progression of inflammatory bowel disease (IBD)-related colorectal cancer (CRC). Read More
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described bicyclic tetrahydrothiazepine derivatives acting as diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer. Read More
